Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ An oral vaccine against coronavirus is being developed as the owner of the LA Lakers

An oral vaccine against coronavirus is being developed as the owner of the LA Lakers



One of the owners of the Los Angeles Lakers is developing a coronavirus vaccine that does not require an injection.

Dr. Patrick Soon-Shiong and his team of researchers are testing whether oral pills could work with – or even better than – vaccines approved by the Food and Drug Administration, CBS Los Angeles reported.

All three vaccines approved for emergency use in the United States – from Pfizer-BioNTech, Moderna and Johnson & Johnson – work by creating antibodies that neutralize the spike protein that coronavirus uses to enter and infect human cells.

But the team’s new vaccine targets the globe-like form in the middle of the virus, which does not often mutate.

In addition, the team says the vaccine would be faster, cheaper and easier to administer because it did not need to be stored in the refrigerator or at freezing temperature.

Researchers from the Chan Soon-Shiong Research Institute are developing a new oral COVID-19 vaccine (above) that targets the global-like form in the middle of the virus

Researchers from the Chan Soon-Shiong Research Institute are developing a new oral COVID-19 vaccine (above) that targets the global-like form in the middle of the virus

One of the developers, dr.  Patrick Soon-Shiong (pictured), co-owner of the Los Angeles Lakers, says the new vaccine would also generate T cells, which bind to and kill viruses.

One of the developers, dr. Patrick Soon-Shiong (pictured), co-owner of the Los Angeles Lakers, says the new vaccine would also generate T cells, which bind to and kill viruses.

‘Having a vaccine that has room temperature that can be a pill is life-changing,’ said one of the investigators, Dr. Tara Seery, from the Chan Soon-Shiong Research Institute of Medicine in El Segundo, California, to CBS Los Angeles.

For the trial, which is currently in Phase I, the team divided volunteers into four groups to see how well the pills work.

One group received only pills, the other group received only one injection, the third group received pills and one injection, and the fourth received none of them.

The new oral vaccine also targets a portion of the coronavirus that is less prone to mutation.

The majority of the most commonly recognized variants, including from the United Kingdom, South Africa and Brazil – have mutations that affect the spike protein of the virus.

This protein is what the coronavirus uses to ‘hijack’ human cells, make multiple copies of itself and spread throughout the body.

But the new oral vaccine attacks the center of the virus known as the lipid bilayer envelope in which the tip protein is anchored.

‘And the value of doing that is that we generate lethal T cells,’ Soon-Shiong told CBS Los Angeles.

T cells are types of white blood cells that bind to and kill viruses.

The team believes that by generating both antibodies and T cells, the recipients would have long-lasting protection.

An average of about three million adults are vaccinated every day, with a single day total reaching four million over the weekend.

An average of about three million adults are vaccinated every day, with a single day total reaching four million over the weekend.

Currently, 108.3 million Americans - 32.6% of the population - have received at least one dose, and 63 million - 19% - are fully immunized

Currently, 108.3 million Americans – 32.6% of the population – have received at least one dose, and 63 million – 19% – are fully immunized

Soon-Chong says the researchers are also testing a combination of an injection and oral vaccines because he thinks we may both need to fight back the virus.

‘By giving a jab, we hope to develop T cells throughout your body,’ he told the station.

‘And by giving orally, we protect the mucous membranes, the intestines and hopefully the nose, the mouth, because that’s how the virus gets in. It does not enter through your blood. ‘

The trial is open to adults between the ages of 18 and 55 who have never tested positive for COVID-19 and are not immunodeficient. Those who want to sign up can visit here.

According to the Centers for Disease Control and Prevention, 108.3 million Americans – 32.6 percent of the population – have received at least one dose and 63 million – 19 percent – are fully immunized.

An average of about three million adults are vaccinated every day, with a single day total reaching four million over the weekend.


Source link